Decreased annexin a2 (anxa2) levels in children with atopic dermatitis: A case-control study

Aim: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in children. The pathogenesis of AD has not been clearly understood. The role of annexin A2 (ANXA2), which is an anti-inflammatory mediator, has not been investigated in the pediatric population with AD. The aim of this study is to investigate serum ANXA2 levels in children with AD. Material and Methods: Three groups were enrolled in this study; an SPT-Pos group (skin prick test positive 25 subjects with AD), an SPT-Neg group (skin prick test negative 25 subjects with AD), and a control group (27 healthy subjects). The serum ANXA2 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: We observed significantly lower serum ANXA2 levels in the disease group than in the control group [0.53 (range 0.14 - 4.38) pg/mL vs 0.94 (range 0.40 - 8.74) pg/mL, respectively; p = 0.01], especially in the SPT-Post group. However, there was no correlation among the parameters of ANXA2, IgE, eosinophil counts. Discussion: ANXA2 may have the role of an anti-inflammatory mediator in the pathogenesis of AD in children. The ANXA2-associated pathways may be considered in the development of novel therapeutic approaches for the treatment of patients with AD.

Automated summary

This study investigated serum ANXA2 levels in children with atopic dermatitis (AD) and found significantly lower levels in the disease group compared to the control group. This suggests a potential role for ANXA2 as an anti-inflammatory mediator in the pathogenesis of AD in children, which may be considered in the development of novel therapeutic approaches for AD patients.